Evidence map›Paper›PMID 36992173›Full record

ArticleVaccines2023

SARS-CoV-2-Neutralizing Antibody Response and Correlation of Two Serological Assays with Microneutralization.

Amal Souiri, Sanaâ Lemriss, Bouchra El Maliki, Hamadi Falahi, Elmostafa El Fahime, Saâd El Kabbaj

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Amal SouiriLaboratory of Research and Medical Analysis of Gendarmerie Royale, Department of Biosafety PCL3, Rabat 10100, Morocco.ORCID 0000-0002-7363-8991
Sanaâ LemrissLaboratory of Research and Medical Analysis of Gendarmerie Royale, Department of Biosafety PCL3, Rabat 10100, Morocco.ORCID 0000-0001-5183-6148
Bouchra El MalikiFaculty of Medecine and Pharmacy, University Hassan II, Casablanca 20250, Morocco.
Hamadi FalahiLaboratory of Research and Medical Analysis of Gendarmerie Royale, Laboratory of Immuno-Serology, Rabat 10100, Morocco.
Elmostafa El FahimeSupporting Unit for Scientific and Technical Research, National Center for Scientific and Technical Research, Rabat 10102, Morocco.
Saâd El KabbajLaboratory of Research and Medical Analysis of Gendarmerie Royale, Department of Biosafety PCL3, Rabat 10100, Morocco.
Laboratoire de Recherche et d’Analyses Médicales de la Fraternelle de la Gendarmerie Royale · MAUniversity of Hassan II Casablanca · MA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SARS-CoV-2 has caused a huge pandemic affecting millions of people and resulting innumerous deaths. A better understanding of the correlation between binding antibodies and neutralizing antibodies is necessary to address protective immunity post-infection or vaccination. Here, we investigate the humoral immune response and the seroprevalence of neutralizing antibodies following vaccination with adenovirus-based vector in 177 serum samples. A Microneutralization (MN) assay was used as a reference method to assess whether neutralizing antibody titers correlated with a positive signal in two commercially available serological tests:a rapid lateral flow immune-chromatographic assay (LFIA) and an enzyme-linked Fluorescence Assay (ELFA). Neutralizing antibodies were detected in most serum samples (84%). COVID-19 convalescent individuals showed high antibody titers and significant neutralizing activity. Spearman correlation coefficients between the serological and neutralization results ranged from 0.8 to 0.9, suggesting a moderate to strong correlation between commercial immunoassays test results (LFIA and ELFA) and virus neutralization.

Indexed as

COVID-19neutralizing antibodySARS-CoV-2serologyvaccination

Identifiers

PMID36992173
PMCPMC10054367
OpenAlexW4323318507

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.